Integration of biochemometrics and molecular networking to identify antimicrobials in Angelica keiskei by Cech, Nadja B. et al.
Integration of biochemometrics and molecular networking to identify antimicrobials in 
Angelica keiskei 
 
By: Lindsay K. Caesar, Joshua J. Kellogg, Olav M. Kvalheim, Richard A. Cech, and Nadja B. 
Cech 
 
Caesar, LK, Kellogg, JJ, Kvalheim, OM, Cech, RA, Cech, NB. (2018) Integration of 
biochemometrics and molecular networking to identify antimicrobials in Angelica keiskei. Planta 
Medica 84(09/10), 721-728. DOI: 10.1055/a-0590-5223 
 
Made available courtesy of Georg Thieme Verlag: http://dx.doi.org/10.1055/a-0590-5223 
 
***© Georg Thieme Verlag KG. Reprinted with permission. No further reproduction is 
authorized without written permission from Georg Thieme Verlag. This version of the 
document is not the version of record. Figures and/or pictures may be missing from this 
format of the document. *** 
 
Abstract: 
 
Botanical medicines have been utilized for centuries. but it remains challenging to identify 
bioactive constituents from complex botanical extracts. Bioassay-guided fractionation is often 
biased toward abundant or easily isolatable compounds. To comprehensively evaluate active 
botanical mixtures, methods that allow for the prioritization of active compounds are needed. To 
this end, a method integrating bioassay-guided fractionation, biochemometric selectivity ratio 
analysis, and molecular networking was devised and applied to Angelica keiskei to 
comprehensively evaluate its antimicrobial activity against Staphylococcus aureus. This 
approach enabled the identification of putative active constituents early in the fractionation 
process and provided structural information for these compounds. A subset of chalcone analogs 
were prioritized for isolation. yielding 4-hydroxyderricin (1, minimal inhibitory concentration 
[MIC] ≤ 4.6 μM, IC50 = 2.0 μM), xanthoangelol (2, MIC ≤ 4.0 μM, IC50 = 2.3) and 
xanthoangelol K (4, IC50 = 168 μM). This approach allowed for the identification of a low-
abundance compound (xanthoangelol K) that has not been previously reported to possess 
antimicrobial activity and facilitated a more comprehensive understanding of the compounds 
responsible for A. keiskei's antimicrobial activity. 
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Article: 
 
Introduction 
 
The complexity of botanicals makes them a rich source for medicinally useful compounds but 
leads to many analytical challenges. The traditional workflow for natural product discovery is 
bioassay-guided fractionation [1-2], in which bioactive extracts and subsequent fractions are 
chromatographically separated and retested for bioactivity until active compounds have been 
isolated. Because botanical extracts contain thousands of individual constituents, it is often 
difficult to assign activity to individual components: thus, the most abundant or easily isolatable 
compounds are often presumed to be responsible for bioactivity [3-4]. New methods are needed 
that will enable isolation efforts to be focused on those components most likely to be responsible 
for the desired biological activity. 
 
Compounds from nature have been utilized to treat microbial infections throughout history [5]. 
and some sources estimate that up to two-thirds of antibacterial agents on today's market are 
derived from natural products [6]. The virtually limit less chemical diversity of natural products, 
particularly botanicals, results from their complex biosynthetic pathways, and many plant 
secondary metabolites, including flavonoids, alkaloids, and coumarins, have shown antimicrobial 
activity (1. 5, 7- 1 OJ. Angelico keiskei Koidzumi (Apiaceae), or ashitaba, is a member of the 
Angelica genus native to the southernmost islands of Japan. and it is popularly utilized as a food 
and a medicinal herb, purportedly to extend life expectancy, increase vitality, and treat a broad 
range of diseases and infections [11]. Most of these activities result from the action of unique 
prenylated chalcones, as well as coumarins and flavanones (reviewed in [12]). Two compounds 
from A. keiskei. 4-hydroxyderricin (1) and xanthoangelol (2), have been shown to possess 
activity against methicillin-resistant Stophyloccoccus oureus (MRSA) [13]. Additionally, A. 
keiskei chalcones xanthoangelol F and isobavachalcone are active against other Gram-positive 
organisms, though they have not been tested against pathogenic bacteria such as MRSA [14]. 
With this study, we sought to employ antimicrobial extracts of A. keiskei as a test case for the 
development of new methods to prioritize bioactive compounds early in the isolation process for 
a complex botanical. 
 
In combination with chromatographic techniques, MS can be utilized to analyze hundreds of 
secondary metabolites simultaneously [3, 15-16]. Using a process called biochemometrics, 
quantitative chemical information and biological activity data can be incorporated into a 
statistical model. With this statistical modeling approach, it is possible to discover chemical 
patterns related to bioactivity [3]. Partial least squares analysis can be used in combination with 
chromatographic and mass spectrometric data to correlate metabolite profiles with biological 
data [17]. A recent study from our laboratory showed that selectivity ratio analysis was useful for 
the identification of trace bioactive constituents in fungal extracts without being confounded by 
highly abundant compounds [3]. The selectivity ratio compares the correlation and covariance to 
the residual variance and provides a quantitative measurement of the ability of a given variable to 
differentiate between active and inactive groups [18]. 
 
Biochemometric analysis is helpful for distinguishing between active and inactive chemical 
constituents. but it is also useful to obtain structural information for the purpose of prioritizing 
new compounds for isolation. To address this, we have utilized the Global Natural Product 
Social Molecular Networking (GNPS) database [19] to build molecular networks from mass 
spectral fragmentation data. These fragmentation data provide useful chemical information. and 
structurally similar molecules should possess similar mass spectral fragmentation patterns. By 
comparing cosine similarity scores of an individual compound's fragmentation patterns. GNPS 
can produce visual networks comprised of chemically related compounds and enables the 
identification of known compounds, molecular families. and structural analogs. By combining 
GNPS networking with biochemometric analysis, we propose that it would be possible to 
identify the structural classes of putative active molecules. The goal of this project is to utilize 
this integrated approach to prioritize isolation efforts on biologically relevant compounds from 
A. keiskei and to gain a more comprehensive understanding of which constituents contribute to 
the antimicrobial activity of this botanical against MRSA. 
 
Table 1. Antimicrobial activity of A. keiskei (AK) crude extract (CR) and second-stage fractions 
AK-3-1 through AK-4-4a 
Sample MRSA growth inhibition (%) 
50 μg/mL 5 μg/mL 
Chloramphenicolb 100 ± 0 46.7 ± 1.8 
AK-CR 99.22 ± 0.39 6.4 ± 6.0 
AK-3-1 0 ± 0b 21 ± 16 
AK-3-2 99.35 ± 0.65 26.0 ± 1.3 
AK-3-3 99.09 ± 0.91 11.14 ± 0.79 
AK-3-4 100 ± 0 0 ± 0 
AK-3-5 90.7 ± 3.3 99.61 ± 0.23 
AK-3-6 0 ± 0b 26 ± 15 
AK-3-7 0 ± 0 0 ± 0 
AK-3-8 0 ± 0 0 ± 0 
AK-4-1 97.4 ± 2.4 19.76 ± 0.26 
AK-4-2 98.8 ± 1.2 98.95 ± 0.47 
AK-4-3 99.74 ± 0.26 3.2 ± 1.2 
AK-4-4 0 ± 0 0.66 ± 0.66 
a Growth Inhibition of MRSA (USA300 LAC strain AH1263) [20] relative to vehicle control measured 
turbidimetrically by OD600. Data presented are the result or triplicate analyses ± standard error of the mean (SEM). 
b Chloramphenicol (Sigma-Aldrich, 98% purity) served as the positive control. b Higher concentration samples or 
AK-3-1 and AK-3-6 show lower activity than their low-concentration counterparts, likely due to low solubility in 
aqueous media at high concentrations. 
 
Results and Discussion 
 
The first goal of this study was to utilize biochemometric analysis to identify putative bioactive 
constituents contributing to the antimicrobial activity of A. keiskei. Bioactivity screening 
demonstrated complete inhibit ion of MRSA (strain USA300 LAC strain AH1263) [20] by the A. 
keiskei extract at 10 μg/mL. This extract was then fractionated in several stages (see fractionation 
schemes. Fig. 1S and 2S, Supporting Information). with the fractions displaying the most 
pronounced antimicrobial activity against MRSA prioritized for further isolation (Table 1). 
 
Bioactivity and mass spectral data from the second stage of fractionation (AK-3-1 through AK-
3-8 and AK-4-1 through AK-4-4) (Table 1) were utilized to produce a biochemometric model 
predicting which constituents were responsible for antimicrobial activity. The internally cross-
validated model generated five components that accounted for 83.61 % of the independent (mass 
spectral) and 99.93% of the dependent (growth inhibition) variation (component 1: 32.58% 
independent, 53.16% dependent; component 2: 24.85% independent, 30.29% dependent; 
component 3: 11.54% independent, 13.98% dependent; component 4: 7.86% independent, 1.93% 
dependent; component 5: 6.79% in dependent, 0.57% dependent). 
 
 
   
Figure 1. Selectivity plot (A) and selected molecular networks of second-stage (B) and third-stage (C) fractions of 
A. keiskei root extract. Bars have been color coded in A and points have been color coded in Band Conly if they 
were both correlated with bioactivity and appeared in molecular networks of interest. Predicted active compounds in 
A appeared almost exclusively in these networks, indicating that a particular class of compounds is responsible for 
A. keiskei's antimicrobial activity. 
 
To interpret the model and tentatively identify the chemical entities responsible for the MRSA 
growth inhibition, a selectivity ratio plot was generated (Fig. 1A). This plot revealed several 
marker ions that were strongly correlated with bioactivity but could not provide structural 
information about these components. To generate such structural information, molecular 
networks were generated using MS/MS data from second-stage and third-stage chromatographic 
fractions (fractions resulting from two or three rounds of chromatographic separation. Fig. l S, 
Supporting Information). The resulting molecular networks were filtered using the 
biochemometric selectivity scores to identify molecular families of putative active compounds 
and assign tentative structures to candidate molecules (Fig. 3S. Supporting Information). 
Interestingly. one second-stage molecular network and one third-stage molecular network 
identified the chalcones 4-hydroxyderricin (1) and xanthoangelol (2). which are the only known 
anti-MRSA compounds from A. keiskei [13]. Other known A. keiskei chalcones were also 
identified (Fig. 2). The same networks also contained masses of seven of the top 10 contributors 
to bioactivity (marker ions A- G. Table 2) based on the biochemometric model (Fig. 1 B, C). 
suggesting that chalcones are responsible for A. keiskei's antimicrobial efficacy against MRSA. 
The combination of biochemometrics and molecular networking enabled identification of a 
subset of these chalcones for prioritization and subsequent analysis, making it possible to predict 
the identity of biologically active extract components prior to isolating them. 
 
Fifteen of the features in networks of interest matched the reported accurate masses of known 
chalcones [12] that have not yet been associated with antimicrobial activity (Fig. 2). Of these, 
five were predicted as potentially contributing to bioactivity by the biochemometric model, 
including the top contributor at m/z 421.202. Two additional compounds in these networks were 
identified among the top 10 contributors by the biochemometric model that did not match 
accurate masses of bioactive chalcones from A. keiskei (Fig. 2). Because these compounds 
clustered with known chalcones based on similarities in mass spectral fragmentation patterns 
(Fig. 2). it was predicted that other chalcone antimicrobials might be present.
 
Figure 2. Molecular networks comprised of compounds detected in A. keiskei built from fractions following one 
(left) and two (right) stages of fractionation. In top networks, compounds marked in red match accurate masses of 
known A. keiskei chalcones. In bottom networks, green compounds match accurate masses of known antimicrobials 
1 and 2, yellow compounds match known chalcones that have not been shown to possess anti-MRSA activity, and 
red compounds were correlated with bioactivity based on biochemometric selectivity ratio analysis but do not match 
known masses from the literature. 
 
Table 2. Tentative identification of putative bioactive chalcones from A. keiskei 
Marker 
Ion 
Ion/retention time 
(molecular formula, 
δ [ppm]) 
Adducts and fragments (molecular formula, δ 
[ppm]) 
Tentative identification(s) 
A 421.202 [M – H]-/6.23 
(C26H29O5-, 1.189) 
 4,2′,4′-trihydroxy-3′-[(2E, 5E)-7-methoxy-3,7-
dimethyl-2,5-octadientyl]chalconea  
Xanthoangelol Ga 
B 391.191 [M – H]-/6.77  
(C25H27O4-, 0.168) 
505.184 [M–H + TFA]- (C25H27O4 + C2HF3O2, 0.399) 
271.134 [M–H – C8H8O]- (C17H19O3-, 2.141 
783.389 [2 M–H]- (2C25H28O4 – H, 0.886) 
Xanthoangelolb 
C 391.191 [M – H]-/5.59  
(C25H27O4-, 0.168) 
 Xanthoangelol Ia 
D 351.123 [M – H]-/5.52 
(C21H19O5-, 0.708) 
 Xanthoangelol Kb 
E 407.186 [M – H]-/6.58 
(C25H27O5-, 0.371) 
 Xanthoangelol Bb 
(2E)-1-[3,5-dihydroxy-2-methyl-2-(4-methyl-3-
[penten-1-yl)-3,4-dyhydroxy-2H-chromen-8-yl]-3-
(4-hydroxyphenyl-2-propen-1-one)a 
(2E)-1-[4-hydroxy-2-(2-hydroxy-6-methyl-5-
hypten-2-yl)-2,3-dihydro-1-benzofuran-5-yl]-3-(4-
hydroxyphenyl)-2-propen-1-onea 
F 379.155 [M – H]-/5.97 
(C23H23O5-, 1.19) 
 Potentially new chalcone derivativec 
G 439.211 [M – H]-/5.17 
(C26H31O6-, 2.422) 
 Potentially new chalcone derivativec 
 
Biochemometric and molecular networking analysis identified marker ions associated with 
activity (Table 2). Purification of active A. keiskei fractions was conducted to assess the 
predictive accuracy of this approach, and four compounds were isolated (Fig. 3). The two known 
anti-MRSA compounds from A. kelskei, 1 and 2. were isolated using a combination of normal- 
and reversed- phase chromatography. Compound 1 was isolated at 98% purity following two 
stages of normal-phase flash chromatography and one stage of reversed-phase flash 
chromatography. Compound 2 was obtained at 95 % purity following three stages of 
fractionation using both normal-phase flash chromatography and reversed-phase preparative-
scale HPLC. The structures of compounds 1 and 2 were confirmed with 1H and 13CNMR by 
comparing to literature data [21] (Fig. 4S-7S, Supporting Information). 
 
 
Figure 3. Structures of compounds 1-4, which were isolated from ashitaba (A. keiskei) and assessed for 
antimicrobial activity 
 
Two additional chalcones, 3 and 4, were isolated following a scale-up extraction and isolation. 
Compound 3 was isolated with 96% purity following two rounds of normal-phase flash 
chromatography, and 4 at 99% purity required an additional round of reversed-phase preparative 
HPLC. 1H and 13CNMR were utilized to confirm the identities of these compounds by comparing 
to published data [22-23] (Fig. 8S-12S, Supporting Information). For 4, HMBC data were 
collected to confirm the presence of a ketone peak that did not appear in the 13CNMR spectra 
(Fig. 12S, Supporting Information), likely due to keto-enol tautomerization. 
 
By integrating biochemometrics and molecular networking into the traditional bioassay-guided 
fractionation workflow, it was possible to prioritize minor constituents in A. keiskei for isolation 
(see workflow, Fig. 3S, Supporting Information). Using biochemometrics to filter molecular 
networks and focus on specific structural classes, a subset of chalcone derivatives were identified 
that were most likely to possess antimicrobial activity and were prioritized for isolation. With 
this method, known, abundant antimicrobial compounds 1 and 2 were isolated, similar to 
previous bioassay-guided fractionation approaches alone [13]. Compounds 1 and 2 demonstrated 
minimal inhibitory concentrations (MICs) against MRSA (USA300 LAC strain AH1263) [20] of 
4.6 μM and 4.0 μM. respectively (Table 3, Fig. 13S, Supporting Information). The 
biochemometrics/GNPS approach also enabled isolation of an additional low-abundance 
antimicrobial compound (4). marker ion D (Table 2). that has not previously been reported to 
possess antimicrobial activity. In selectivity ratio plots, 4 was listed as the fourth top contributor 
to the observed biological activity of A. keiskei despite its low relative abundance (Fig. 1A, Table 
2). In the base-peak chromatogram of the A. keiskei root extract, the peak area associated with 4 
only accounted for 0.8% or the total Fraction (Fig. 4). Compound 4 did inhibit growth of MRSA 
(IC50 at 168 μM, Table 3, Fig. 13S, Supporting Information) but did not reach MIC at the highest 
concentration tested (284 μM). Finally, as additional confirmation, we also isolated 3, which 
appeared in the chalcone molecular network (Fig. 2) but was not predicted to be antimicrobial. 
As predicted by biochemometrics, 3 did not possess antimicrobial activity, despite structural 
similarity to active compounds. Collectively, the agreement between predicted and observed 
biological activity of 1-4 demonstrates that the biochemometrics process as employed can be 
effective for identifying a subset or molecules for isolation based on their likely biological 
activity. 
 
Table 3. MIC and IC50 data for compounds 1-4 against MRSA (USA300 LAC strain AH1263) 
[20] relative to vehicle control measured turbidimetrically by OD600. Presented data were 
calculated using four-parameter logistic curves of triplicate data 
Compound MICa IC50 
1 4.6 μM 2.0 μM 
2 4.0 μM 2.3 μM 
3 – – 
4 – 168 μM 
a The MIC value expressed is likely higher than the actual MIC value, which lies somewhere between the lowest 
tested concentration that inhibited bacterial growth and the highest tested concentration that did not completely 
inhibit bacterial growth [27]. 
 
 
Figure 4. Base-peak chromatogram of ethyl acetate A. keiskei root extract with peaks of interest identified by 
biochemometric selectivity ratio analysis. This analysis was successful in enabling prioritization of trace peaks of 
interest for isolation. 
 
The results described here are consistent with previous studies that suggest that prenyl and 
geranyl moieties on the A-ring of chalcones (present in 1 and 2) are associated with 
antimicrobial activity (14). Compound 3 has a markedly different side chain from 1 and 2, with a 
Flexible peroxide group, which is likely responsible for its decreased antimicrobial activity. 
Compound 4, though it does not contain a prenyl side chain. could possess weak activity due to 
the similarity of its side chain in rigidity and size to the prenyl substituent seen in 1. 
 
Several additional features identified as possibly contributing to biological activity were 
identified in GNPS as chemically related to isolated chalcones 1-4 (Fig. 1 and 2). Based on these 
networks and accurate mass data of these compounds. we tentatively identified these compounds 
(Table 2). Unfortunately, material was too limited to isolate these compounds or assess 
biological activity. From a drug discovery stand point, however, this approach is useful in 
dereplication, as it allowed us to identify these compounds as chalcones early in the fractionation 
process. Since chalcones are well documented antimicrobials (24), we did not complete an 
additional scale-up to pursue their isolation. 
 
In this example, marker ion A (Table 2) at m/z [M – H]- 421.202 eluting at 6.2 min was identified 
as the constituent most correlated with bioactivity and accounted for 0.4% of the total extract 
based on peak area. Unfortunately, even with a scale-up extraction and chromatographic efforts 
tailored to this specific compound, isolation efforts for this compound were unsuccessful. This 
failure to isolate the active constituent demonstrates one of the inherent limitations of the 
biochemometric approach for identifying bioactive compounds. While it is possible based on 
mass spectrometric data to identify minor compounds that may have important biological 
activity, it may be infeasible (due to limited quantity) to isolate such minor compounds for 
confirmation of structure and activity. 
 
One limitation of this study is that biochemometric analysis did not predict biological activity for 
the most abundant isotopes of 1 and 2, despite the confirmed antimicrobial activity of these 
compounds. Based on relative peak area, 2 accounted for 37.8 % of the relative abundance in the 
EtOAc extract, and 1 accounted for 12.5%. The high abundance and antimicrobial potency of 
these compounds likely led to a mismatch in biological and chemical data. While the relative 
peak area of these compounds varied in every fraction under study, the biological activity was 
saturated at 100% in multiple fractions. Consequently, the linearity between the relative 
abundance of these compounds and their corresponding bioactivity was likely skewed, leading to 
false negative results. Although the [M – H]- peak for the most abundant (12C) isotope of 2 was 
not identified as active (Fig. 1). several of the 13C isotopes as well as the TFA adduct, and an in-
source fragment of this compound were predicted to be active (marker ion B, Table 2). The 
adducts and isotopes of 2 were only evident in fractions where 2 was extremely abundant. and 
consequently, they were identified by the selectivity score as marker ions related to bioactivity. 
The identification of an active isotope of a compound that is not itself predicted to be active is 
dearly an artifact of an error in the data analysis process, given that all isotopes co-occur in the 
sample, and the adducts are formed in the ionization process and likely not present in the sample 
at all. 
 
An important goal for the comprehensive characterization of a botanical medicine should be to 
isolate minor constituents within the extract. However, it is not feasible to isolate all minor 
constituents in a complex mixture, so putative bioactive constituents must be prioritized. A major 
strength of the biochemometric selectivity ratio analysis is its ability to identify low-abundance 
constituents contributing to activity without being confounded by compounds of high abundance. 
However, this strength comes with an important weakness in that bioactive compounds of high 
abundance may be overlooked. This weakness can easily be overcome, however, if this statistical 
analysis is incorporated into the traditional bioassay-guided fractionation workflow, which 
favors the isolation of abundant active compounds. It is also possible that this limitation could be 
addressed by diluting samples to reduce the level of high-abundance compounds, although this 
approach would come at the expense of sacrificing response of those present at low abundance. 
 
In combination with bioassay-guided fractionation, biochemometrics and molecular networking 
can be utilized to identify structural families of putative active constituents present at very low 
levels, allowing for the prioritization of isolation of both high- and low-abundance components 
that contribute to activity or, alternately, enabling the dereplication of known bioactive 
compounds and their structural analogs. The latter application is important because it prevents 
time being wasted on re-isolating known active compounds. Had we been searching for bioactive 
compounds with novel structures only, we may have chosen not to pursue further isolation with 
A. keiski once we identified chalcones as the major class of active constituents within this plant. 
However, for the purpose of this study, a botanical containing known antimicrobial constituents 
served as a useful test case. The approach employed here not only facilitated the identification of 
a trace antimicrobial constituent from A. keiskei, but also yielded new and more complete 
information about which constituents are responsible for the antimicrobial activity of this 
botanical. Additionally, it provided insight into which structural characteristics of chalcones are 
associated with their antimicrobial effects. 
 
Materials and Methods 
 
General experimental procedures 
 
NMR spectra were obtained using a JEOL ECA-500 MHz spectrometer. UPLC-MS analysis was 
completed in both negative and positive modes using an LTQ Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific) connected to an Acquity UPLC system (Waters Corporation). When 
collecting UPLC-MS data, 3 μl of 1 mg/mL samples suspended in MeOH were injected into the 
column. Using a flow rate of 0.3 mL/min, samples eluted from the column (BEH C18 1.7 μm, 
2.1 × 50 mm, Waters Corporation) using the following gradient with solvent A consisting of 
water with 0.1 % formic acid and solvent B consisting of acetonitrile with 0.1 % formic acid: 
90:10 (A:B) from 0-0.5 min, increasing to 0:100 (A:B) from 0.5-8.0 min. The gradient was held 
at 100% B for 0.5 min before returning to starting conditions over 0.5 min and held from 9.0-
10.0 min. Mass analysis was completed in both positive and negative ionization modes over a 
scan range of 150-2000 with the following settings: capillary voltage at -21.00V, capillary 
temperature at 275.00°C, tube lens offset at -95.00V, spray voltage at 3.50 kV, sheath gas flow at 
30.00, and auxiliary gas flow at 15.00. The top four most intense ions were fragmented with CID 
set to 35.0. 
 
Flash chromatographic separations were completed using a CombiFlash RF system (Teledyne-
Isco) and examined using a PDA detector and an evaporative light scattering detector. 
Preparative and analytical HPLC separations were conducted with a Varian HPLC system 
(Agilent Technologies) using Galaxie Chromatography Workstation software (version 1.9.3.2, 
AgilentTechnologies). All chemicals were acquired through Sigma-Aldrich and were 
spectroscopic or microbiological grade. 
 
Plant material 
 
Fresh roots or A. keiskei were collected on November 14, 2015, from Strictly Medicinal Seeds in 
Williams, Oregon (Sample #12421, N 42°12'17.211", W 123°19'34.60). Scale-up material was 
completed using plant material from the same source collected on December 29, 2016 (Sample 
#12444, N 42°12' 17.211", W 123°19'34.60). The identity of this plant material was confirmed 
by Richard A. Cech at Strictly Medicinal Seeds. and a voucher specimen was deposited at the 
herbarium or the University of North Carolina at Chapel Hill (NCU627665). 
 
Extraction 
 
Fresh A. keiskei roots were dried in a single-wall transite oven (Blue M Electric Company) at 
40°C for 24 h. The resulting dry mass (138.90 g) was ground using a Wiley Mill Standard Model 
No. 3 (Arthur Thomas Company) and submerged in MeOH at 160 g/L for 24 h three times. The 
resulting MeOH extract was concentrated in vacuo and then subjected to liquid-liquid extraction. 
First, the extract was defatted by partitioning between 10% aqueous MeOH and hexane (1:1). 
The dried aqueous MeOH layer was partitioned further between 4:5:1 EtOAc/MeOH/H20. To 
remove hydrosoluble tannins, the EtOAc layer was washed with a 1% NaCl solution. The 
resulting EtOAc extract was dried under nitrogen, yielding 3650.32 mg dried extract, before 
further experimentation. Scale-up material (964 g) was dried, extracted. and partitioned using the 
same methods listed above, ultimately yielding 18.10 g or dried EtOAc extract for subsequent 
chromatographic separation. 
 
Chromatographic separation and isolation 
 
The isolation scheme is provided as Supporting Information (Fig. 1S and 2S, Supporting 
Information). The first-stage separations of the EtOAc extract (3100 mg) were conducted using 
normal-stage flash chromatography (40-g silica gel column) at a 40-mL/min flow rate with a 35-
min hexane/CHCl3/MeOH gradient. The last two fractions (AK-3 and AK-4)were subjected to a 
second stage of normal -phase f lash chromatography. Fraction 3 (AK-3, 1355 mg) was separated 
again with a 40-g silica gel column at a flow rate of 40 mL/min, and fraction 4 (AK-4, 536 mg) 
was separated on a 12-g silica column with a flow rate of 30 mL/min. Each run lasted 45 min and 
was completed using a hexane/EtOAc/MeOH gradient. The most active fraction from the 
separation of AK-3 (fraction 2, AK-3-2, 1000 mg) was subjected to a final round of reversed-
phase flash chromatography using a 130-g C18 reversed phase RediSep Rf column with an 85-
mL/min flow rate. A 25-min gradient of CH3CN/H2O was used, starting at 40:60 and increasing 
to 85:15. It was increased to 100:0 for 5 min. upon which starting conditions were reestablished. 
Compound 1 eluted at 18 min (234.45 mg, 98% purity, 7.6% yield). Fraction AK-4-2 (364 mg) 
was also subjected to a final round of reversed-phase preparative HPLC injected onto a Luna 
preparatory column (5 μm PFP, 250 × 21.20 mm: Phenomenex). The 35-min run began at 40:60 
CH3CN:H2O and was increased to 100:0 over 30 min. Compound 2 was collected from 28-35 
min (284.59 mg, 95% purity, 9.1% yield). 
 
Compounds 3 and 4 were isolated following scale-up extraction. First, 17.5 g of EtOAc extract 
were separated on a 120-g silica column with an 85-mL/min flow rate using the same 
hexane/CHCl3/MeOH gradient as used for the first fractionation of original extract. The second 
fraction (S-AK-2, 5.3 g) was separated again using normal-phase flash chromatography on a 
120-g silica column at 85 mL/min flow rate with a 55-min gradient of hexane/EtOAc/MeOH. 
Compound 3 eluted at 31 min (150 mg, 96% purity, 0.85% yield). Fraction 4 (S-AK-2-4, 172 
mg) was subjected to a final 45-min round of reversed-phase preparative HPLC on a Gemini-NX 
preparatory column (5 μm C18, 250 × 21.20mm: Phenomenex) at a flow rate of 21.4 mL/min 
with a gradient of 55:45 CH3CN:H2O. Compound 4 (1.5mg, 99% purity, 0.0086% yield) eluted 
at 19 min. 
 
4-hydroxyderricin (1): yellow crystalline solid: HRESIMS m/z 337.1438 [M – H]- (calculated for 
C21H21O4-, 337.1440); 1H NMR (500 MHz. CDCl3) and 13C NMR (125 MHz. CDCl3) chemical 
shifts matched literature values [25] and are provided in Supporting Information (Fig. 4S and 
5S). 
 
Xonthoangelol (2): yellow crystalline solid: HRESIMS m/z 391.1907 [M – H]- (calculated for 
C25H27O4-, 391.1909); 1H NMR (500 MHz. CDCl3) and 13C NMR (125 MHz. CDCl3) chemical 
shifts matched literature values [25] and are provided in Supporting Information (Fig. 6S and 
7S). 
 
Xonthoangelol E (3): yellow. amorphous powder; HRESIMS m/z 369.1340 [M – H]- (calculated 
for C21H21O6-, 369.1338); 1H NMR (500MHz, DMSO)and 13C NMR (125MHz, DMSO) 
chemical shifts matched literature values [22] and are provided in Supporting Information (Fig. 
8S and 9S). 
 
Xonthoangelol K (4): yellow amorphous powder; HRESIMS m/z 351.1231 [M – H]- (calculated 
for C21H19O5-, 351.1232); 1H NMR (500 MHz, CDCl3), 13C NMR (125 MHz, CDCl3), and 
HMBC (400MHz, CDCl3) chemical shifts matched literature values [23] and are provided in 
Supporting Information (Fig. 10S-12S). 
 
Antimicrobial assay 
 
Antimicrobial activity was monitored by assessing growth inhibition of a laboratory strain of S. 
aureus (SA1199) [26] and a clinically relevant strain of MRSA (USA300 LAC strain AH1263) 
[20] obtained from Dr. Alexander Horswill at the University of Colorado Anschutz Medical 
Campus. Cultures were grown from a single colony isolate of each strain in Mueller-Hinton 
broth (MHB) and diluted to 1.0 x 105 CFU/mL based on absorbance at 600 nm (OD600). 
 
Samples were screened in triplicate at final concentrations of 10 and 100 μg/mL or 5 and 50 
μg/mL. Samples were dissolved in 1:1 EtOH/DMSO (v/v) and diluted with MHB to prepare final 
concentrations in broth with less than 2% EtOH/DMSO. The known antibiotic chloramphenicol 
(98% purity, Sigma-Aldrich) was used as a positive control at the same concentrations as tested 
ex tracts. The vehicle was 2% EtOH/DMSO in MHB. Each well was inoculated with bacteria 
and incubated for 24 h at 37 °C. OD600 was evaluated after incubation and used to calculate the 
percent growth inhibition. All fractions were subjected to analysis and active fractions were 
chosen for further fractionation. 
 
MICs were calculated for pure compounds based on the Clinical Laboratory Standards Institute 
standard protocols [27]. Isolated compounds or chloramphenicol (positive control, 98% purity. 
Sigma-Aldrich) were added to 96-well plates in triplicate at concentrations ranging from 0-100 
μg/mL in MHB. Broth containing 2% 1:1 EtOH/DMSO was used as the vehicle control. The 
concentration of EtOH/DMSO was set at a fixed value of 2% for all wells. After a 24-h 
incubation at 37°C. OD600 values were measured using a Synergy Hl microplate reader (Biotek). 
The MIC was defined as the concentration at which no statistically significant difference 
between the blank wells (containing sample and broth but no bacteria) and the treated sample 
was observed. . 
 
Biochemometric analysis 
 
LC-MS data were collected in both negative mode and positive mode and individually analyzed, 
aligned, and filtered utilizing MZmine 2.21.2 (http://mzmine.sourceforge.net/) [28]. Raw mass 
spectral data files from second-stage fractions were uploaded for peak picking into MZmine 
based upon m/z values within each spectrum above a set baseline for all batch samples. 
Chromatograms were constructed for all m/z values lasting longer than 0.1 min, following which 
they were deconvoluted using algorithms that were applied to chromatograms to recognize 
individual peaks. The peak detection parameters were set as follows: noise level (absolute value) 
at 1.25 × 106 (positive mode) and at 2 × 106 (negative mode), minimum peak duration at 0.5s, 
m/z variation tolerance at 0.05, and m/z intensity variation tolerance at 20%. Peaks were aligned 
if their masses were within 5 ppm and their retention times were a maximum of 0.15 min from 
one another. Peak list filtering and retention time alignment were completed to produce an 
aligned peak list. The resulting data matrix, consisting or m/z, retention time, and peak area. was 
imported into Excel (Microsoft) and merged with bioactivity data from samples at tested at 5 
μg/ml to form the final data set for biochemometric analysis. 
 
Biochemometric analysis was completed using Sirius version 10.0 statistical software (Pattern 
Recognition Systems) [29]. Before analysis, data were adjusted using a fourth root 
transformation to normalize noise across treatments [30]. An internally cross-validated partial 
least squares model was then produced using 100 iterations and a significance level of 0.05. 
Statistical algorithms internal to the Sirius software utilized model predictions to produce 
selectivity ratios identifying putative antimicrobial constituents. 
 
Molecular networking analysis 
 
Mass spectral data were converted to mzXML format using FileZilla version 3.14. 1, part or the 
ProteoWizard platform [31]. Following file conversion, mass spectral and fragmentation data 
were uploaded to the GNPS data analysis portal in three groups, where fractions active at 5 
μg/ml were included in group 1, fractions active at 50 μg/ml were included in group 2, and 
inactive fractions were included in group 3. These data were then combined into consensus 
spectra using the MS-clustering algorithm [32] within the GNPS database [19]. 
 
Molecular networks were produced using the online GNPS workflow. First. MS/MS peaks 
within 17 Da of the precursor m/z were removed. and only the top six fragment peaks were 
compared for analysis. Using MS-Cluster. consensus spectra were produced with a parent mass 
tolerance of 0.5 Da and an MS/MS fragmention tolerance of 0.3 Da. Consensus spectra 
containing fewer than 10 spectra were discarded. Molecular networks were subsequently 
produced, and compounds were connected if they had a cosine score (similarity score) above 
0.65 and more than six matched fragment peaks. If more than 10 compounds shared a cosine 
score above this threshold with a given compound, only the top 10 most similar compounds were 
connected. Parameters for third-stage fractions were the same, except that the minimum cluster 
size was adjusted to 100. Fragmentation patterns were compared to databases within GNPS, 
including the GNPS Library, the GNPS-NIH-Natural Products Library, GNPS Prestwick 
Phytochemical Library, and the RESPECT Library to tentatively identify components matching 
MS/MS patterns already contained within the system. Networks were viewed in GNPS using the 
network visualizer in addition to being imported to Cytoscape (33) for visualization. To simplify 
investigation of networks, nodes containing accurate masses identified by biochemometric 
analysis as putative active compounds were prioritized for structural characterization. 
 
Supporting Information 
 
The isolation scheme, workflow, NMR spectra, and dose response curves are available as 
Supporting Information. 
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